Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

473
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

825
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
825
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

484
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
484
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

398
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
398
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

523
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
523
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

1.3K
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States.

Blood advances·2026
Same author

Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses.

Seminars in thrombosis and hemostasis·2026
Same author

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.

Journal of pediatric hematology/oncology·2026
Same author

Seventh Ă…land Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Menstrual Health & Heavy Menstrual Bleeding in Congenital Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?

Therapeutic advances in hematology·2026

Related Experiment Video

Updated: Apr 17, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.9K

Management of VWD.

Anne T Neff1, Robert F Sidonio2

  • 1Departments of Medicine and Pathology, Microbiology & Immunology and.

Hematology. American Society of Hematology. Education Program
|February 20, 2015
PubMed
Summary

Von Willebrand disease (VWD) is a common inherited bleeding disorder due to VWF molecule issues. Management requires accurate diagnosis and tailored treatments, including VWF concentrates and new therapies, to control bleeding risks.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.3K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Related Experiment Videos

Last Updated: Apr 17, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.9K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.3K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Von Willebrand disease (VWD) is the most prevalent inherited bleeding disorder.
  • It stems from deficiency or dysfunction of the von Willebrand Factor (VWF) molecule.
  • Bleeding risk in VWD ranges from mild procedural bleeding to severe spontaneous hemorrhage.

Purpose of the Study:

  • To review the current and emerging management strategies for VWD.
  • To highlight the complexities in managing VWD, particularly in women.
  • To discuss novel therapeutic approaches for VWD.

Main Methods:

  • Review of existing literature on VWD diagnosis and treatment.
  • Analysis of current therapeutic options including desmopressin and VWF concentrates.
  • Exploration of emerging treatments and management challenges.

Main Results:

  • Optimal VWD management involves precise diagnosis and individualized treatment selection.
  • Current treatments focus on increasing endogenous VWF or providing exogenous concentrates.
  • Special considerations are needed for managing bleeding in women and patients with antibodies to VWF.

Conclusions:

  • Effective VWD management hinges on accurate diagnosis of the specific type.
  • A combination of established and novel therapies, tailored to the clinical scenario, is crucial.
  • Future therapies like recombinant VWF and IL-11 show promise for improved VWD treatment.